Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. [electronic resource]
Producer: 20170713Description: 305-13 p. digitalISSN:- 1573-7241
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents -- adverse effects
- Apolipoproteins B -- blood
- Cholesterol -- blood
- Double-Blind Method
- Ezetimibe -- adverse effects
- Female
- Humans
- Hypercholesterolemia -- blood
- Male
- Middle Aged
- PCSK9 Inhibitors
- Treatment Outcome
- Triglycerides -- blood
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.